×

Adib Saberi, Dr. Fereshte

Publikationsverzeichnis

Adib Saberi, F (1994) Gibt es Prädiktoren für das frühe Behandlungsschicksal nach einmaliger Botulinustoxin-Behandlung bei Patienten mit idiopathischen Torticollis spasmodicus? Medizinische Dissertation Hamburg (Deneke).

Dressler D, Adib Saberi F, Benecke R (2002) Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 249(12):1729-1732.

Wittstock M, Adib Saberi F, Benecke R, Dressler D (2002) Botulinum toxin treatment of axillar hyperhidrosis. Naunyn Schmiedebergs Arch Pharmacol 365 (Suppl 2):R48.

Wittstock M, Adib Saberi F, Benecke R, Dressler D (2002) Botulinum Toxin zur Behandlung fokaler Hyperhidrosen. 60. Jahrestagung der Gesellschaft für Nervenheilkunde des Landes Mecklenburg-Vorpommern e.V., Rostock, Deutschland, 25.10.-27.10.2002.

Adib Saberi F, Dressler D (2004) „Spastische Syndrome: Behandlung mit der intrathekalen Baclofen-Therapie (ITB). Ärzte-Broschüre Medtronic GmbH.

Dressler D, Adib Saberi F (2005) Botulinum toxin: therapeutic mechanisms of action. Eur Neurol 53(1):3-9.

Dressler D, Adib Saberi F, Reis Barbosa E (2005) Botulinum toxin: Therapeutic mechanisms of action. Arq Neuropsiquiatr 63:180-185.

Dressler D, Adib Saberi F (2006): First high dose use of complex-free botulinum toxin type A. 10th International Congress of Parkinson’s Disease and Movement Disorders Kyoto, Japan, 28.10.-02.11.2006. Movement Disorders 21(supplement 2):S640.

Dressler D, Adib Saberi F (2006) Safety Aspects of High Dose Xeomin® Therapy. 16th Meeting European Neurological Society, Lausanne, Switzerland, 27.-31.05.2006. J Neurol 253(Suppl 2):141-142.

Dressler D, Adib Saberi F (2006) Erste Erfahrungen mit der Hochdosis-Anwendung einer komplexfreien Botulinum Toxin-Präparation. Akt Neurol 33: S60.

Dressler D, Adib Saberi F (2006) First high dose use of complex free botulinum toxin type A. Mov Disord 21(Suppl 15):S640.

Dressler D, Adib Saberi F (2007) New formulation of BOTOX®: Complete antibody-induced therapy failure in cervical dystonia. J Neurol Neurosurg Psychiat J 78(1):108-109.

Dressler D, Adib Saberi F (2007) Cranial Dystonias. In: Bressman S, Warner T (Eds) Clinical Diagnosis and Management of Dystonia. Martin Dunitz/Taylor & Francis, London.

Adib F, Schade H, Dressler D (2007) Botulinum toxin to treat parotid saliva retention after iatrogenic Stenon duct lesion. 11th International Congress of Parkinson’s Disease and Movement Disorders, Istanbul, Turkey, June 3-7, 2007.

Adib Saberi F, Schade H, Dressler D (2008) Botulinum toxin to treat parotid saliva retention after transient postoperative Stenon´s duct occlusion. Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins Baveno, Lake Maggiore, Italy, June 12-14, 2008. Toxicon 51:44, DOI: 10.1016/j.toxicon.2008.04.132.

Adib Saberi F, Dressler D (2008) Muscle hyperactivity after stroke: long term follow up of prevalence and current treatment practice. 12th International Congress of Parkinson’s Disease and Movement Disorders, Chicago, USA June 22-26, 2008.

Adib Saberi F, Czolbe F, Dressler D (2008) Muskeltonuserhöhungen nach zerebrovaskulären Ereignissen. Akt Neurol 35/S1:154. DOI: 10.1055/s-0028-1087016.

Saberi FA, Schade H, Dressler D (2008) Botulinum toxin to treat parotid saliva retention after transient postoperative Stenon’s duct occlusion. Toxicon 51 (Suppl 1): 44-44.

Adib Saberi F, Czolbe F, Dressler D (2008) Muskeltonuserhöhungen nach zerebrovaskulären Ereignissen. 81. Jahrestagung der Deutschen Gesellschaft für Neurologie, Hamburg, Deutschland, 10.-13.09.2008.

Dressler D, Adib Saberi F (2009) Muscle hyperactivity after stroke: Long term follow up of prevalence and current treatment. Movement Disorders 24(Suppl1):S449-S449.

Müller K, Mix E, Adib Saberi F, Dressler D, Benecke R (2009) Prevalence of neutralizing antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm 116(5):579-585.

Dressler D, Adib Saberi F (2009) Botulinum Toxin: Vom Medikament zum Toxin. Akt Neurol (Suppl 1) S49-54.

Dressler D, Adib Saberi F (2009) Botulinum Toxin: from drug to poison. Fortschritte der Neurologie · Psychiatrie (Impact Factor: 0.85). 08/2009; 77 Suppl 1:S49-54. DOI: 10.1055/s-0028-1109615

Adib Saberi F, Dressler D (2009) Muscle hyperactivity after stroke: Long term follow up of prevalence and current treatment. Mov Disord 24/Suppl 1: S449.

Dressler D, Adib Saberi F (2009) Chemodenervation in PD and other Movement Disorders. 13th International Congress of Parkinson’s Disease and Movement Disorders, Paris, France, June, 7-11, 2009.

Adib Saberi F, Dressler D (2009) Muscle hyperactivity after stroke: long term follow up of prevalence and current treatment practice. 13th International Congress of Parkinson’s Disease and Movement Disorders Paris, France, June, 7-11, 2009.

Dressler D, Adib Saberi F (2009) Chemodenervation in Parkinson’s Disease and other Movement Disorders. International Meeting „Movement Disorders in Focus“, Cebu Philippine November 18-19, 2009.

Adib Saberi F, Bigalke H, Dressler D (2009) Antigenicity differences between Botox® and Xeomin®: Studied in a patient with transient botulinum toxin antibody titres. J Neural Transm 117: 1229-1229.

Adib Saberi F, Bigalke H, Dressler D (2010) Antigenicity differences between botulinum toxin drugs. Movement Disorders 25(Suppl2):S227-S227.

Adib Saberi F, Bigalke H, Dressler D (2010) Antigenicity differences between Botox® and Xeomin®: Study in a patient with transient neutralizing botulinum toxin antibody formation. First International Congress on Treatment of Dystonia, Hannover Deutschland, 6.-8.5.2010.

Adib Saberi F, Bigalke H, Dressler D (2010) Antigenicity differences between Botox® and Xeomin®. 14th International Congress of Parkinson’s Disease and Movement Disorders Buenos Aires, Argentina June 13-17, 2010. Abstract 125:86. Volume: 25.

Dressler D, Adib Saberi F (2010) Pharmakologie der Botulinum Toxin-Medikamente. in: Laskawi R, Vogt T (2010) Botulinum Toxin Typ A: Praktische Anwendungen. Thieme, Stuttgart:2-10.

Dressler D, Adib Saberi F, Pickenbrock H (2010) Entspannung per Spritze Physiopraxis 11-12: 40-41.

Dressler D, Adib Saberi F, Pickenbrock H (2010) Entspannung per Spritze. Ergopraxis 11-12: 24-25.

Adib Saberi F, Dressler D (2011) Interdisciplinary Special Interest Groups (ISIG) for optimizing multimodal therapy of movement disorders. 15th International Congress of Parkinson’s Disease and Movement Disorders Toronto, Canada June 5-9, 2010. Abstract 139:90. Movement Disorders 26(supplement 2):S47.

Adib Saberi F (2011) Interdisziplinärer Arbeitskreis Bewegungsstörungen. Dystonie aktuell 34, Frühjahr 2011:10-11.

Adib Saberi F, Pickenbrock H, Dressler D (2011) Communication calendar for botulinum toxin therapy of spasticity in an outpatient setting. 7th International Conference on span lang=“EN-GB“>Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins span lang=“EN-GB“>Santa Fe, New Mexico, USA, October 2-5, 2011.

Adib Saberi F, Dressler D (2011) Interdisciplinary Special Interest Groups (ISIG) for optimizing multimodal therapy of movement disorders. INTERNATIONAL SYMPOSIUM DYSTONIA AND DYSTONIC SYNDROMES. The Czech Movement Disorder Society PALACKÝ UNIVERSITY ARTS CENTRE, OLOMOUC, CZECH REPUBLIC, December 8 – 9, 2011 Mov Dis 26 (Suppl 2): S47-S47.

Adib Saberi F (2012) IAB AS AN EXAMPLE FOR INTERDISCIPLINARY SPECIAL INTEREST GROUPS (ISIG) FOR OPTIMIZING MULTIMODAL THERAPY OF MOVEMENT DISORDERS. 8th International Congress on Mental Dysfunction in Parkinson’s Disease and & Other Non-Motor Features in Other Related Disorders Germany, Berlin May 3-6 2012

Adib Saberi F, Pickenbrock H, Dressler D (2012) Communication form for optimizing multimodal therapy of movement disorders. 16th International Congress of Parkinson’s Disease and Movement Disorders Dublin, Ireland June 17-21, 2012, Abstract 872:105. Mov Disord 27 (Suppl 1): S292-S293.

Adib Saberi F, Pickenbrock H, Dressler D (2012) Interdisziplinärer Arbeitskreis Bewegungsstörungen (IAB) zur Optimierung multimodaler Therapie von Bewegungsstörungen. 85. Kongress der Deutschen Gesellschaft für Neurologie mit Fortbildungsakademie, 26.-29. September 2012, Hamburg, Poster 760.

Adib Saberi F, Dressler D (2012) Interdisziplinärer Arbeitskreis Bewegungsstörungen (IAB): an interdisciplinary working group for promoting multimodal therapy of movement disorders. J Neural Transm DOI 10.1007/s00702-012-0932-6

Adib Saberi F, Pickenbrock H, Dressler D (2013) Communication calendar for botulinum toxin therapy of spasticity in an outpatient setting. Toxicon 68:104, DOI: 10.1016/j.toxicon.2012.07.123.

Adib Saberi F, Pickenbrock H, Dressler D (2013) Development of a webpage as a communication platform for optimising multimodal therapy of movement disorders. The Botulinum J., Vol. 2, Nos. 3/4: 208.

Adib Saberi F, Dressler D (2013) Interdisziplinärer Arbeitskreis Bewegungsstörungen (IAB): A new approach for promoting interdisciplinary therapy of movement disorders. J Neural Transm 120:705-710.

Dressler D, Adib Saberi F (2013) Linking allied health care professionals and physicians: the IAB model. Journal of Neural Transmission 120:1137.

Dressler D, Adib Saberi F (2013) Towards a dose optimistaion of botulinum toxin therapy for axillary hyperhidrosis: Comparison of different botox doses. J Neural Transm 2013 Nov;120(11):1565-7. doi: 10.1007/s00702-013-1021-1. Epub 2013 Jun 14.

Adib Saberi F (2013) IAB – Interdisziplinärer Arbeitskreis Bewegungsstörungen. Dystonie Rundblick, Sommer 2013: 10-12

Dressler D, Adib Saberi F (2013) Botulinum toxin in myotonia congenita: it does not help against rigidity and pain. Journal of Neural Transmission (Impact Factor: 3.05). 12/2013; DOI: 10.1007/s00702-013-1136-4.

Adib Saberi F, Pickenbrock H, Dressler D (2013) Development of a webpage as a communication platform for optimising multimodal therapy of movement disorders. The Botulinum J., Vol. 2, Nos. 3/4: 208.

Dressler D, Adib Saberi F, Kollewe K, Schrader C (2014) Safety aspects of incobotulinumtoxinA high-dose therapy. Journal of neural transmission (Vienna, Austria : 1996) 07/2014; DOI: 10.1007/s00702-014-1252-9.

Dressler D, Adib Saberi F, Bigalke H (2014) IncobotulinumtoxinA (Xeomin(®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport(®). Journal of Neural Transmission (Impact Factor: 3.05). 03/2014; DOI: 10.1007/s00702-014-1165-7.

Adib Saberi, F., Dressler, D. (2014) The dystonia discomfort scale (DDS): A self-assessment scale for monitoring the temporal profile of botulinum toxin therapy in dystonia [abstract]. Movement Disorders 2014; 29 Suppl 1 :475

Dressler D, Adib Saberi F, Kollewe K, Schrader C (2014) Safety aspects of high-dose incobotulinumtoxinA therapy [abstract]. Movement Disorders 2014;29 Suppl 1 :834

Dressler D, Tacik P, Adib Saberi F (2014), Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. Journal of neural transmission (Vienna, Austria : 1996) 07/2014; DOI: 10.1007/s00702-014-1253-8

Dressler D, Tacik P, Adib Saberi F (2014) Botulinum Toxin Therapy of Cervical Dystonia: Comparing Botox® and Xeomin®. J Neural Transm 121:29-31.

Adib Saberi F, Dressler D (2014) Interdisciplinary Treatment of Dystonia: The IAB Example. In: Bleton JP, Treatment of Cervical Dystonia. Edition Frissault-Roche, Paris

Dressler D, Adib Saberi F, Bigalke H (2014) IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®). J Neural Transm 121:769-771.

Dressler D, Tacik P. Adib Saberi F (2014) Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm 122:297-300.

Dressler D, Adib Saberi F, Kollewe K, Schrader C (2014) Safety aspects of incobotulinumtoxinA high dose therapy. J Neural Transm 122:327-333.

Adib Saberi F, Dressler D, Moreno M, Micheli F (2014) Un grupo Interdisciplinario (GTI) para promover la terapia multimodal en trastornos del movimiento. Prensa Médic Argent 100:484-491.

Dressler D, Berweck S, Chatzikalfas A, Ebke M, Frank B, Hesse S, Huber M, Krauss JK, Mücke K-H, Nolte A, Oelmann H-D, Schönle PW, Schmutzler M, Pickenbrock H, Van der Ven C, Veelken N, Vogel M, Vogt T, Adib Saberi F (2015) Intrathecal baclofen therapy in Germany: proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders consensus meeting. J Neural Transm 122:1573-1579.

Adib Saberi F, Pickenbrock H, Dressler D (2015) The ComCal to Facilitate the Communication between Physicians and Physiotherapists in Botulinum Toxin Therapy of Spasticity. Toxins 93:S55, DOI: 10.1016/j.toxicon.2014.11.179.

Adib Saberi F, Pickenbrock H, Dressler D (2015) Usefulness of Communication Calendar for Botulinum Toxin Therapy of Spasticity in an Outpatient Setting. Conference: 19th International Congress of Parkinson’s Disease and Movement Disorders June 14 – 18, 2015, San Diego, CA, USA, Volume: Volume 30, June 2015 Abstract, Volume 30, June 2015 Abstract Supplement / Movement Disorders 2015;30 Suppl 1 :4163.

Dressler D, Altenmueller E, Bhidayasiri R, Boholega S, Chana P, Chung TM, Frucht S, Garcia-Ruiz PJ, Kaelin A, Kaji R, Kanovsky P, Laskawi R, Micheli F, Orlova O, Relja M, Rosales R, Slawek J, Timerbaeva S, Warner TT, Adib Saberi F (2015) Strategies for Treatment of Dystonia. J Neural Transm 123:251-258.

Dressler D, Adib Saberi F, Bigalke H (2016) Botulinum Toxin Therapy: Reduction of Injection Site Pain by pH-normalisation. J Neural Transm 123:527-531.

Dressler D, Vogt S, Adib Saberi F (2016) Der Off-Label Use am Beispiel der Botulinumtoxin-Therapie. Klin Neurophysiol 47: 87-91.

Dressler D, Adib Saberi F (2016) Safety of botulinum toxin short interval therapy using incobotulinumtoxin A. Journal of Neural Transmission 124(4). DOI: 10.1007/s00702-016-1628-0.

Dressler D, Bhidayasiri R, Bohlega S, Chahidi A, Mo Chung T, Ebke M, Jacinto LJ, Kaji R, Koçer S, Kanovsky P, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Adib Saberi F (2017) Botulinum Toxin Therapy for Treatment of Spasticity in Multiple Sclerosis: Review and Recommendations of the IAB – Interdisciplinary Working Group for Movement Disorders Task Force. J Neurol 264:112-120.

Dressler D, Adib Saberi F (2017) Immunological safety of incobotulinumtoxinA (Xeomin®) therapy with reduced interinjection intervals. J Neural Transm 124:437-440.

Dressler D, Adib Saberi F (2017) Economics of botulinum toxin therapy: influence of the abobotulinumntoxinA package size on the costs of botulinum toxin therapy. Mov Dis Clin Pract 4:6.

Dressler D, Adib Saberi F (2017) Rehabilitation of Dystonia. In: Chien HF, Barsottini O (Eds) Movement Disorders Rehabilitation. Springer, New York. pp67-82.

Dressler D, Gelderblohm M (2017) Dystonie. In: Brandt T, Diener HC, Gerloff C (Eds) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart, Germany. pp 1120-1130.

Adib Saberi F, Dressler D (2018) Linking allied Health Professionals and Physicians: The IAB Model. In: Dressler D, Altenmüller E, Krauss JK (Eds) Treatment of Dystonia. Cambridge University Press, Cambridge, UK.

Dressler D, Bhidayasiri R, Boholega S, Chana P, Chien S, Chung TM, Colosimo C, Ebke M, Fedoroff K, Frank B, Kaji R, Kanovsky P, Koçer S, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Adib Saberi F (2018) Defining Spasticity: A New Approach Considering Current Movement Disorders Terminology and Botulinum Toxin Therapy. J Neurol 265:856-862.

Dressler D, Pan L, Adib Saberi F (2018) Antibody-induced Failure of Botulinum Toxin Therapy: Re-Start with Low-Antigenicity Drugs Offers a New Treatment Opportunity. J Neural Transm 125:1481-1486.

Dressler D, Ebke M, Adib Saberi F, Schrader C (2018) Botulinum toxin therapy in patients with oral anticoagulation: is it safe? Toxicon 156:S26. DOI: 10.1016/j.toxicon.2018.11.064.

Pan L,  Adib Saberi F, Jin L, Dressler D (2018) Comparing hengli® with onabotulinumtoxinA and incobotulinumtoxinA: Identical potency labeling in the mouse diaphragm assay. Toxicon 156:S87. DOI: 10.1016/j.toxicon.2018.11.211.

Adib Saberi F, Dressler Dc (2019) Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease. [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/communication-calendar-for-interdisciplinary-therapy-of-parkinsons-disease-2/. Accessed November 6, 2020.

Dressler D, Pan L, Adib Saberi F, Bigalke H (2019) Do Complexing Proteins provide mechanical Protection for Botulinum Toxin Neurotoxins? J Neural Transm 126:1047-1050.

Dressler D, Adib Saberi F (2020) Botulinum Toxin Therapy in the SARS-CoV-2 Pandemic: Patient Perceptions from a German Cohort. J Neural Transm 127:1271-1274.

Dressler D, Adib Saberi F, Rosales R (in press) Botulinum toxin therapy of dystonia. J Neural Transm.